According to the latest report by IMARC Group, titled “Anti-Obesity Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," the global anti-obesity drugs market size reached US$ 2.0 Billion in 2022. Anti-obesity drugs are pharmacological agents that reduce or control body weight by lowering cholesterol levels. They suppress appetite, inhibit fat absorption, and increase energy consumption and thermogenesis. Anti-obesity drugs are widely used by patients suffering from morbid obesity, impaired glucose tolerance, and low high-density lipoprotein (HDL) cholesterol. They are also used by frequent snackers, nocturnal eaters, individuals with uncontrollable appetites, and those requiring immediate weight loss for medical reasons. Anti-obesity drugs increase metabolic rate, promote satiety, offer sustained weight loss, and assist patients in achieving long-lasting obesity control. They also provide independent health benefits, such as decreased blood pressure, improved insulin sensitivity, reduced harmful lipid levels, and lower risk of cardiovascular and diabetic kidney diseases.
Global Anti-Obesity Drugs Market Trends:
The rising prevalence of obesity due to sedentary lifestyles, unhealthy eating habits, genetic susceptibility, and lack of physical exercise is one of the primary factors driving the market growth. Anti-obesity drugs are widely used to manage obesity, achieve higher weight loss, and treat binge-eating disorders, as they inhibit intestinal fat absorption, suppress food intake, increase energy consumption, and enhance metabolism. Furthermore, rising incidences of obesity-associated comorbidities, such as type 2 diabetes, hypertension, metabolic syndrome, stroke, dyslipidemia, myocardial infarction, sleep apnea, osteoarthritis, and certain cancers, are acting as another growth-inducing factor. In line with this, anti-obesity drugs improve glycemic control, reduce glycated hemoglobin levels, and positively impact cardiometabolic risk factors, such as blood pressure, waist circumference, lipid profile, and insulin sensitivity, which, in turn, is favoring the market growth. Additionally, the recent development of next-generation products that are safer, highly efficient, and provide sustained body weight loss due to the improved understanding of molecular gut-brain communication is positively influencing the market growth. Moreover, the rising adoption of combination therapies that provides greater weight loss, higher efficiency, and minimal side effects is propelling the market growth. Other factors, including the rising geriatric population, significant growth in the healthcare industry, increasing investments in research and development (R&D) activities to formulate novel drugs, and rising concerns regarding perioperative mortality and surgical complications, are anticipated to drive the market growth. On account of the aforementioned factors, the market value is expected to reach US$ 4.0 Billion by 2028, exhibiting a CAGR of 11.7% during 2023-2028.
- On the basis of the drug class, the market has been divided into peripherally and centrally acting drugs.
- Based on the drug type, the market has been bifurcated into prescription and OTC drugs.
- On the basis of the distribution channel, the market has been classified into hospital, retail, and online pharmacies.
- On a regional basis, the market has been categorized into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and Others), Latin America (Brazil, Mexico, and Others), and Middle East and Africa.
- The competitive landscape of the industry has also been examined, with some of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.
|Base Year of the Analysis
||Drug Class, Drug Type, Distribution Channel, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800